Venture Life Group PLC
LSE:VLG
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.4
65.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Venture Life Group PLC
Venture Life Group Plc engages in the development, manufacture, and commercializing of products for the aging population. The company is headquartered in Bracknell, Berkshire and currently employs 119 full-time employees. The company went IPO on 2014-03-28. The firm is focused on developing, manufacturing and commercializing products for the global self-care market. The firm's segments include Brands, which includes sales of healthcare and skin care products under distribution agreements and direct to United Kingdom retailers, and Development and Manufacturing. Through its two Development and Manufacturing operations in Italy and Sweden, the Company also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. Its product portfolio includes the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
Venture Life Group Plc engages in the development, manufacture, and commercializing of products for the aging population. The company is headquartered in Bracknell, Berkshire and currently employs 119 full-time employees. The company went IPO on 2014-03-28. The firm is focused on developing, manufacturing and commercializing products for the global self-care market. The firm's segments include Brands, which includes sales of healthcare and skin care products under distribution agreements and direct to United Kingdom retailers, and Development and Manufacturing. Through its two Development and Manufacturing operations in Italy and Sweden, the Company also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. Its product portfolio includes the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
Revenue Growth: Group revenue rose 43% to GBP 15.4 million, with 12.5% organic growth, driven by both UK consumer brands and international markets.
Health & Her Acquisition: The Health & Her business contributed GBP 4 million in the first half, boosting reported growth and improving margins due to higher product profitability.
Margin Expansion: Gross margin increased to 43.1%, up from 41.2% last year, aided by the mix shift from higher-margin brands.
Marketing Investment: Marketing spend rose to 10.5% of group sales (14.5% on supported brands), targeting brand awareness and long-term revenue acceleration.
Cash Position & Firepower: Following the CDMO divestment, net cash was GBP 34 million at September end, with up to GBP 85 million available for acquisitions.
Brand Performance: Strong growth in women's health (Balance Activ up 24%) and Health & Her (up 35%), but energy management brands declined due to a temporary NHS ordering issue.
Strategic Refocus: The company completed its shift to a capital-light, brand-led model, divesting manufacturing and non-core brands to focus on high-margin categories.
Outlook: Management is confident in continued organic growth, margin improvement, and upcoming acquisitions, with a strong emphasis on innovation, digital, and international expansion.